Overview

Pilot Study of Erlotinib for the Treatment of Patients With de Novo Acute Myeloid Leukemia

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This research study is looking for patients with newly diagnosed acute myeloid leukemia (AML), AML that has returned (relapsed), or it has not responded adequately to previous treatments. Treating certain patients with chemotherapy may not be to their benefit or may cause more harm than benefit. The purpose of this study is to find out what effects (good and bad) erlotinib has on patients and their AML.
Phase:
Phase 2
Details
Lead Sponsor:
Indiana University
Collaborator:
OSI Pharmaceuticals
Treatments:
Erlotinib Hydrochloride